Name | (2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate |
---|---|
Synonyms |
trimazosine
TRIMAZOSIN EINECS 252-732-7 |
Description | Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenoceptors[1][2]. |
---|---|
Related Catalog | |
Target |
α1-adrenergic receptor |
In Vivo | Trimazosin (10–30 mg/kg; i.h.; once) produces graded decreases in blood pressure[3]. Animal Model: Conscious spontaneously hypertensive rats (SHR)[3] Dosage: 10–30 mg/kg Administration: Subcutaneous administration, once Result: Produced graded decreases in blood pressure. |
References |
[2]. H L Elliott, et al. Trimazosin in normotensive subjects. Clin Pharmacol Ther. 1984 Feb;35(2):156-60. |
Density | 1.31g/cm3 |
---|---|
Boiling Point | 648.2ºC at 760mmHg |
Molecular Formula | C20H29N5O6 |
Molecular Weight | 435.47 |
Flash Point | 345.8ºC |
Exact Mass | 435.21200 |
PSA | 132.50000 |
LogP | 1.85140 |
Index of Refraction | 1.606 |